 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Medicine > Vion Pharmaceuticals, Inc.
 |
Vion Pharmaceuticals, Inc. |
 |
 |
 |
PROFILE |
 |
Vion Pharmaceuticals wants to bring forth the scion of cancer treatment. The development-stage firm, however, has suffered a setback. Its lead anti-cancer product, Promycin, which targets radiation-resistant oxygen-depleted tumor cells, failed to meet expectations in trials for head and neck cancer, so partner Boehringer Ingelheim has curtailed development. Vion focuses now on TAPET (tumor amplified protein expression therapy), drug delivery technology that uses genetically altered Salmonella strains to deliver anticancer drugs. TAPET itself may fight melanoma and breast, colon, and lung cancer with minimized side effects. Other drug candidates include Triapine, designed to prevent tumor cells from replicating.
COMPETITION |
 |
Cell Therapeutics, Inc. (CTIC)
GenStar Therapeutics Corporation (GNT)
Genzyme Molecular Oncology (GZMO)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 0.90
1-Yr. Sales Growth: (71.9)%
Employees: 54
Revenue per employee: $16,666.67
KEY PEOPLE |
 |
Alan Kessman
CEO
Steven H. Koehler
CFO
CONTACT INFO |
 |
4 Science Park
New Haven, CT 06511
US
Phone: 203-498-4210
Fax: 203-498-4211
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |